Loading stock data…
$20.24-0.12 (-0.59%)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $20.24 with a market capitalization of $58.9B. Wall Street consensus targets $22.87 (3 analysts), implying a +13.0% move over the next 12 months. The stock is currently near its 52-week high of $20.39, remaining 16.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.22T↑ | $1.09T↓ | $1.19T↑ | $1.11T↑ | $1.11T |
| Gross Profit | $813.22B↑ | $688.84B↓ | $790.55B↑ | $732.74B↑ | $722.01B |
| Operating Income | $201.42B↑ | $42.07B↓ | $168.82B↑ | $69.00B↓ | $184.56B |
| Net Income | $113.20B↑ | -$368.47B↓ | $103.64B↑ | -$11.80B↓ | $124.24B |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therap...